Management Team
About Us
Our Story
Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Our lead product candidate, omilancor (BT-11), is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. In January 2021, the Company reported initial results from a Phase 2 proof-of-concept trial of omilancor in patients with mild to moderate ulcerative colitis (UC). Landos expects to initiate a Phase 3 trial of omilancor in UC patients as well as a Phase 2 trial of omilancor for the treatment of moderate to severe Crohn’s disease (CD) in the first half of 2021.
The Company’s mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm for autoimmune disease.
